Learning from best scalp cooling practices in a registry: differences in results from n>7000 patients with solid tumors

Journal of Clinical Oncology 37, no. 15_suppl (May 20, 2019) 11610-11610.

Type:

Poster

Link:

https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.11610

DOI:

10.1200/JCO.2019.37.15_suppl.11610

Authors:

C J G van den Hurk¹, M W Dercksen², J W R Nortier³, W P M Breed⁴

Author Affiliations:

¹Netherlands Comprehensive Cancer Organisation (IKNL)
²Maxima Medical Center
³Leiden University Medical Center
⁴Catharina Hospital

Abstract

Purpose

Hair loss is a frequently occurring and stigmatizing side effect of chemotherapy. Worldwide scalp cooling is being introduced to prevent chemotherapy-induced alopecia (CIA). In the Netherlands scalp cooling is implemented in many hospitals since 2005. FDA clearance has been approved for scalp cooling among breast cancer patients in the USA in 2016. Recently approval has been expended for solid tumors.

DOWNLOAD POSTER

Learning from best scalp cooling practices in a registry: differences in results from n>7000 patients with solid tumors

Association Between Use of a Scalp Cooling Device and Alopecia After Chemotherapy for Breast Cancer

Scalp Cooling in Preventing Persistent Chemotherapy-Induced Alopecia: A Randomized Controlled Trial

Persistent Alopecia and Docetaxel – Low Incidence, High Impact